Clinical Use of a Monoclonal Antibody to Bombesin‐like Peptide in Patients with Lung Cancer a, b

Small cell lung cancer (SCLC) is one of four major types of lung cancer and constitutes roughly 25% of all the new cases. Unfortunately, despite major improvements in overall patient survival as a result of combination chemotherapy, over 90% of all SCLC patients die of their tumor.’,’ More effective treatments are clearly needed. Drug development programs based on empiric screening of various compounds have been successful for treatment of certain tumors, but not of lung cancer, despite massive investments of time and money.’*‘ Many cancer investigators feel that therapeutic progress for lung cancer will be made by exploiting the increased understanding of tumor cell biology in order to use rationally based therapies. The observation that a monoclonal antibody which binds to gastrin-releasing

[1]  I. Todd.  Cancer of the Lung , 1975, British Journal of Cancer.

[2]  D. Carlo,et al.  Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. , 1984, Blood.

[3]  M. Sporn,et al.  Autocrine secretion and malignant transformation of cells. , 1980, The New England journal of medicine.

[4]  J. Weinstein,et al.  Immunolymphoscintigraphy of pulmonary and mediastinal lymph nodes in dogs: a new approach to lung cancer imaging. , 1987, Cancer research.

[5]  J. Mulshine,et al.  Treatment of non-small-cell lung cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Mulshine,et al.  Consideration of the Chemistry of Solid‐Phase Matrix Interactions Leads to Improved Quantitation of Neuropeptides a, b , 1988, Annals of the New York Academy of Sciences.

[7]  H. Kung,et al.  c-erbB activation in avian leukosis virus-induced erythroblastosis: clustered integration sites and the arrangement of provirus in the c-erbB alleles. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[8]  K. Foon,et al.  Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. , 1985, Cancer research.

[9]  G. Bepler,et al.  Establishment and identification of small cell lung cancer cell lines having classic and variant features. , 1985, Cancer research.

[10]  J. Minna,et al.  Small cell lung cancer 1973-1983: early progress and recent obstacles. , 1984, International journal of radiation oncology, biology, physics.

[11]  J. Weinstein,et al.  Immunolymphoscintigraphy and the dose dependence of 111In-labeled T101 monoclonal antibody in patients with cutaneous T-cell lymphoma. , 1987, Cancer research.

[12]  J. Minna,et al.  Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. , 1988, The Journal of clinical investigation.

[13]  D. Kaufman,et al.  Secretion of an insulin-like growth factor-I-related protein by human breast cancer cells. , 1986, Cancer research.

[14]  R. Bell.  Protein kinase C activation by diacylglycerol second messengers , 1986, Cell.

[15]  J. Minna,et al.  Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. , 1985, Cancer research.

[16]  G. Krejcarek,et al.  Covalent attachment of chelating groups to macromolecules. , 1977, Biochemical and biophysical research communications.

[17]  J. Mulshine,et al.  Indium-111 T101 monoclonal antibody is superior to iodine-131 T101 in imaging of cutaneous T-cell lymphoma. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  M. Berridge,et al.  The molecular basis of communication within the cell. , 1985, Scientific American.

[19]  A. Gazdar,et al.  Radioimmunodetection of cutaneous T-cell lymphoma with 111In-labeled T101 monoclonal antibody. , 1986, The New England journal of medicine.

[20]  A. Ullrich,et al.  Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences , 1984, Nature.

[21]  P. Bunn,et al.  Monoclonal Antibody Therapy for Patients with Leukemia and Lymphoma , 1985 .

[22]  R. Oldham.  Patient-funded cancer research. , 1987, The New England journal of medicine.

[23]  John D. Minna,et al.  Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer , 1985, Nature.

[24]  S. Larson,et al.  IMAGING OF T-CELL LYMPHOMA BY RADIOLABELLED MONOCLONAL ANTIBODY , 1984, The Lancet.